methyl 1-azabicyclo[3.1.1]hept-5-ylcarboxylate | 133998-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 1-azabicyclo[3.1.1]hept-5-ylcarboxylate
• 英文别名: methyl 1-azabicyclo[3.1.1]heptane-5-carboxylate
• CAS: 133998-45-5
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: BNLADMZNTHDOIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 1-azabicyclo[3.1.1]hept-5-ylcarboxylate 、 N-羟基己脒 生成 5-(3-Pentyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[3.1.1]heptane oxalate salt
  参考文献：
  名称：

  Certain 5-substituted-1-aza-bicyclo[3.3.3]heptanes and their

  摘要：

  化合物式(I)或其药学上可接受的盐：##STR1## 其中Z是杂环基团##STR2## 其中Q表示完成5-成员芳香环的3-成员双价残基，并包括从氧、氮和硫中选择的一个或两个杂原子，或三个氮原子，任何氨基氮被C.sub.1-2烷基，环丙基或丙炔基取代，任何环碳原子可被R.sub.1基团取代;或者是一个群##STR3## 其中A.sub.1、A.sub.2和A.sub.3完成一个5-成员芳香环，A.sub.1是氧或硫，A.sub.2和A.sub.3中的一个是CR.sub.2，另一个是氮或CR.sub.3，或者是A.sub.2是氧或硫，A.sub.1和A.sub.3中的一个是CR.sub.2，另一个是CR.sub.3;R.sub.1、R.sub.2和R.sub.3独立选择自氢、卤素、CN、OR.sub.4、SR.sub.4、N（R.sub.4）.sub.2、NHCOR.sub.4、NHCOOCH.sub.3、NHCOOC.sub.2 H.sub.5、NHOR.sub.4、NHNH.sub.2、NO.sub.2、COR.sub.4、COR.sub.5、环丙基、C.sub.2-5直链烯基、C.sub.2-5直链炔基或C.sub.1-5直链烷基，可选地末端取代OR.sub.4、N（R.sub.4）.sub.2、SR.sub.4、CO.sub.2 R.sub.4、CON（R.sub.4）.sub.2或一、二或三个卤素原子，其中每个R.sub.4独立地为氢或C.sub.1-3烷基，R.sub.5为OR.sub.4、NH.sub.2或NHR.sub.4;或者Z是一个群--C（R.sub.7）.dbd.NR.sub.6，其中R.sub.6是一个OR.sub.8群，其中R.sub.8是C.sub.1-4烷基，C.sub.2-4烯基，C.sub.2-4炔基，OCOR.sub.9群，其中R.sub.9是氢或R.sub.8，或NHR.sub.10或NR.sub.11R.sub.12群，其中R.sub.10、R.sub.11和R.sub.12独立地为C.sub.1-2烷基，R.sub.7为氢或C.sub.1-4烷基，但当R.sub.6是OCOR.sub.9或NHR.sub.10时，R.sub.7为C.sub.1-4烷基。

  公开号：

  US05043343A1

文献信息

• Certain 5-substituted-1-azabicyclo[3.1.1]heptanes and their
  申请人：Beecham Group p.l.c.

  公开号：US05157160A1

  公开（公告）日：1992-10-20

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which Z is a heterocyclic group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R.sub.1 ; or a group ##STR3## in which A.sub.1, A.sub.2 and A.sub.3 complete a 5-membered aromatic ring and A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.2 and the other is nitrogen or CR.sub.3, or A.sub.2 is oxygen or sulphur, one of A.sub.1 and A.sub.3 is CR.sub.2 and the other is CR.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen, halogen, CN, OR.sub.4, SR.sub.4, N(R.sub.4).sub.2, NHCOR.sub.4, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sub.4, NHNH.sub.2, NO.sub.2, COR.sub.4, COR.sub.5, cyclopropyl, C.sub.2-5 straight chain alkenyl, C.sub.2-5 straight chain alkynyl or C.sub.1-5 straight chain alkyl optionally terminally substituted with OR.sub.4, N(R.sub.4).sub.2, SR.sub.4, CO.sub.2 R.sub.4, CON(R.sub.4).sub.2 or one, two or three halogen atoms, in which each R.sub.4 is independently hydrogen or C.sub.1-3 alkyl and R.sub.5 is OR.sub.4, NH.sub.2 or NHR.sub.4 ; or in which Z is a group --C(R.sub.7).dbd.NR.sub.6 in which R.sub.6 is a group OR.sub.8, where R.sub.8 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, a group OCOR.sub.9 where R.sub.9 is hydrogen or R.sub.8, or a group NHR.sub.10 or NR.sub.11 R.sub.12 where R.sub.10, R.sub.11 and R.sub.12 are independently C.sub.1-2 alkyl and R.sub.7 is hydrogen or C.sub.1-4 alkyl, subject to the proviso that when R.sub.6 is a group OCOR.sub.9 or NHR.sub.10, R.sub.7 is C.sub.1-4 alkyl. The compounds are potentially useful in the treatment of diseases of the nervous system.

  化合物的公式为(I)或其药学上可接受的盐：##STR1## 其中Z是一个杂环基团##STR2## 其中Q代表一个3元的二价残基，完成一个5元芳香环，并包括一个或两个从氧、氮和硫中选择的杂原子，或三个氮原子，任何氨基氮原子被C.sub.1-2烷基、环丙基或丙炔基取代，任何环碳原子被R.sub.1基团取代；或者是一个基团##STR3## 其中A.sub.1、A.sub.2和A.sub.3完成一个5元芳香环，其中A.sub.1为氧或硫，A.sub.2和A.sub.3中的一个为CR.sub.2，另一个为氮或CR.sub.3，或者A.sub.2为氧或硫，A.sub.1和A.sub.3中的一个为CR.sub.2，另一个为CR.sub.3；R.sub.1、R.sub.2和R.sub.3独立地选择自氢、卤素、CN、OR.sub.4、SR.sub.4、N(R.sub.4).sub.2、NHCOR.sub.4、NHCOOCH.sub.3、NHCOOC.sub.2 H.sub.5、NHOR.sub.4、NHNH.sub.2、NO.sub.2、COR.sub.4、COR.sub.5、环丙基、C.sub.2-5直链烯基、C.sub.2-5直链炔基或C.sub.1-5直链烷基，可选择地末端取代为OR.sub.4、N(R.sub.4).sub.2、SR.sub.4、CO.sub.2 R.sub.4、CON(R.sub.4).sub.2或一个、两个或三个卤素原子，其中每个R.sub.4独立地是氢或C.sub.1-3烷基，R.sub.5是OR.sub.4、NH.sub.2或NHR.sub.4；或者Z是一个基团--C(R.sub.7).dbd.NR.sub.6，其中R.sub.6是一个基团OR.sub.8，其中R.sub.8是C.sub.1-4烷基、C.sub.2-4烯基、C.sub.2-4炔基、一个OCOR.sub.9基团，其中R.sub.9是氢或R.sub.8，或者一个NHR.sub.10或NR.sub.11R.sub.12基团，其中R.sub.10、R.sub.11和R.sub.12独立地是C.sub.1-2烷基，R.sub.7是氢或C.sub.1-4烷基，但当R.sub.6是OCOR.sub.9或NHR.sub.10时，R.sub.7是C.sub.1-4烷基。这些化合物在治疗神经系统疾病方面具有潜在的用途。
• Azabicyclic compounds
  申请人：Beecham Group p.l.c.

  公开号：EP0413545A2

  公开（公告）日：1991-02-20

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which Z is a heterocyclic group in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C1 -2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R1 ; or a group in which A1 , A2 and A3 complete a 5-membered aromatic ring and A1 is oxygen or sulphur, one of A2 and A3 is CR2 and the other is nitrogen or CR3, or A2 is oxygen or sulphur, one of A1 and A3 is CR2 and the other is CR3; and R1, R2 and R3 are independently selected from hydrogen, halogen, CN, OR4, SR4, N(R4)2, NHCOR4, NHCOOCH3, NHCOOC2H5, NHOR4, NHNH2, N02, COR4, COR5, cyclopropyl, C2-5 straight chain alkenyl, C2-5 straight chain alkynyl or C1-5 straight chain alkyl optionally terminally substituted with OR4, N(R4)2, SR4, C02R4, CON(R4)2 or one, two or three halogen atoms, in which each R4 is independently hydrogen or C1-3 alkyl and R5 is OR4, NH2 or NHR4; or in which Z is a group -C(R7) = NR6 in which R6 is a group OR8, where R8 is C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, a group OCOR9 where R9 is hydrogen or R8, or a group NHR10 or NR11R12 where R10, R11 and R12 are independently C1 -2 alkyl and R7 is hydrogen or C1 -4 alkyl, subject to the proviso that when R6 is a group OCOR9 or NHR10, R7 is C1-4 alkyl.

  式 (I) 的化合物或其药学上可接受的盐： 其中 Z 是杂环基团 其中 Q 代表完成 5 元芳香环的 3 元二价残基，包含 1 个或 2 个选自氧、氮和硫的杂原子，或 3 个氮原子，任何氨基氮被 C1 -2 烷基、环丙基或丙炔基取代，任何环碳原子任选被基团 R1 取代；或一个基团 其中 A1、A2 和 A3 组成一个五元芳香环，且 A1 为氧或硫，A2 和 A3 中的一个为 CR2，另一个为氮或 CR3，或 A2 为氧或硫，A1 和 A3 中的一个为 CR2，另一个为 CR3；C2-5直链烯基、C2-5直链炔基或C1-5直链烷基，任选被OR4、N(R4)2、SR4、C02R4、CON(R4)2或一个、两个或三个卤素原子末端取代，其中每个R4独立为氢或C1-3烷基，R5为OR4、NH2或NHR4；或 Z 为基团-C(R7) = NR6，其中 R6 为基团 OR8，R8 为 C1-4 烷基、C2-4 烯基、C2-4 炔基、基团 OCOR9（其中 R9 为氢或 R8）或基团 NHR10 或 NR11R12（其中 R10、R11 和 R12 独立为 C1-2 烷基，R7 为氢或 C1-4 烷基），但当 R6 为基团 OCOR9 或 NHR10 时，R7 为 C1-4 烷基。
• US5043343A
  申请人：——

  公开号：US5043343A

  公开（公告）日：1991-08-27
• US5157160A
  申请人：——

  公开号：US5157160A

  公开（公告）日：1992-10-20
• Certain 5-substituted-1-aza-bicyclo[3.3.3]heptanes and their
  申请人：Beecham Group p.l.c.

  公开号：US05043343A1

  公开（公告）日：1991-08-27

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## in which Z is a heterocyclic group ##STR2## in which Q represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, or three nitrogen atoms, any amino nitrogen being substituted by a C.sub.1-2 alkyl, cyclopropyl or propargyl group, and any ring carbon atom being optionally substituted by a group R.sub.1 ; or a group ##STR3## in which A.sub.1, A.sub.2 and A.sub.3 complete a 5-membered aromatic ring and A.sub.1 is oxygen or sulphur, one of A.sub.2 and A.sub.3 is CR.sub.2 and the other is nitrogen or CR.sub.3, or A.sub.2 is oxygen or sulphur, one of A.sub.1 and A.sub.3 is CR.sub.2 and the other is CR.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen, halogen, CN, OR.sub.4, SR.sub.4, N(R.sub.4).sub.2, NHCOR.sub.4, NHCOOCH.sub.3, NHCOOC.sub.2 H.sub.5, NHOR.sub.4, NHNH.sub.2, NO.sub.2, COR.sub.4, COR.sub.5, cyclopropyl, C.sub.2-5 straight chain alkenyl, C.sub.2-5 straight chain alkynyl or C.sub.1-5 straight chain alkyl optionally terminally substituted with OR.sub.4, N(R.sub.4).sub.2, SR.sub.4, CO.sub.2 R.sub.4, CON(R.sub.4).sub.2 or one, two or three halogen atoms, in which each R.sub.4 is independently hydrogen or C.sub.1-3 alkyl and R.sub.5 is OR.sub.4, NH.sub.2 or NHR.sub.4 ; or in which Z is a group --C(R.sub.7).dbd.NR.sub.6 in which R.sub.6 is a group OR.sub.8, where R.sub.8 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, a group OCOR.sub.9 where R.sub.9 is hydrogen or R.sub.8, or a group NHR.sub.10 or NR.sub.11 R.sub.12 where R.sub.10, R.sub.11 and R.sub.12 are independently C.sub.1-2 alkyl and R.sub.7 is hydrogen or C.sub.1-4 alkyl, subject to the proviso that when R.sub.6 is a group OCOR.sub.9 or NHR.sub.10, R.sub.7 is C.sub.1-4 alkyl.

  化合物式(I)或其药学上可接受的盐：##STR1## 其中Z是杂环基团##STR2## 其中Q表示完成5-成员芳香环的3-成员双价残基，并包括从氧、氮和硫中选择的一个或两个杂原子，或三个氮原子，任何氨基氮被C.sub.1-2烷基，环丙基或丙炔基取代，任何环碳原子可被R.sub.1基团取代;或者是一个群##STR3## 其中A.sub.1、A.sub.2和A.sub.3完成一个5-成员芳香环，A.sub.1是氧或硫，A.sub.2和A.sub.3中的一个是CR.sub.2，另一个是氮或CR.sub.3，或者是A.sub.2是氧或硫，A.sub.1和A.sub.3中的一个是CR.sub.2，另一个是CR.sub.3;R.sub.1、R.sub.2和R.sub.3独立选择自氢、卤素、CN、OR.sub.4、SR.sub.4、N（R.sub.4）.sub.2、NHCOR.sub.4、NHCOOCH.sub.3、NHCOOC.sub.2 H.sub.5、NHOR.sub.4、NHNH.sub.2、NO.sub.2、COR.sub.4、COR.sub.5、环丙基、C.sub.2-5直链烯基、C.sub.2-5直链炔基或C.sub.1-5直链烷基，可选地末端取代OR.sub.4、N（R.sub.4）.sub.2、SR.sub.4、CO.sub.2 R.sub.4、CON（R.sub.4）.sub.2或一、二或三个卤素原子，其中每个R.sub.4独立地为氢或C.sub.1-3烷基，R.sub.5为OR.sub.4、NH.sub.2或NHR.sub.4;或者Z是一个群--C（R.sub.7）.dbd.NR.sub.6，其中R.sub.6是一个OR.sub.8群，其中R.sub.8是C.sub.1-4烷基，C.sub.2-4烯基，C.sub.2-4炔基，OCOR.sub.9群，其中R.sub.9是氢或R.sub.8，或NHR.sub.10或NR.sub.11R.sub.12群，其中R.sub.10、R.sub.11和R.sub.12独立地为C.sub.1-2烷基，R.sub.7为氢或C.sub.1-4烷基，但当R.sub.6是OCOR.sub.9或NHR.sub.10时，R.sub.7为C.sub.1-4烷基。